Aspirin dry powder inhalation - Otitopic
Alternative Names: ASPRIHALE; OTI-0726Latest Information Update: 28 May 2023
At a glance
- Originator Otitopic
- Class Analgesics; Antineoplastics; Antiplatelets; Antipyretics; Antirheumatics; Heart failure therapies; Nonsteroidal anti-inflammatories; Salicylic acids; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Lung cancer; Myocardial infarction
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Lung-cancer in USA (Inhalation, Powder)
- 28 Dec 2022 No recent reports of development identified for clinical-Phase-Unknown development in Myocardial-infarction in USA (Inhalation, Powder)
- 09 Aug 2021 Otitopic has been acquired by Philip Morris International